Nordic Pharma is working with Spirit Access

By on September 21, 2018

Spirit Access and Nordic Pharma announce joint working programme

Nordic Pharma enlists Spirit Access to analyse and drive value from the current NHS rheumatoid arthritis patient pathway

Founded in 2002, Nordic Pharma UK, was one of the first European affiliate companies of the Nordic Group of companies. Over the last 15 years, Nordic Pharma has worked with the NHS to supply essential and hard to obtain medicines to help the NHS meet patient needs. Nordic Pharma has partnered with Spirit Access to gain a better understanding of the rheumatoid arthritis patient pathway and to identify opportunities to add value to the pathway by the introduction of its methotrexate auto-injector PEN and its potential associated services.

Nordic Pharma is confident that its methotrexate auto-injector PEN will add real value to the NHS pathway for patients; however, further insight and data was required to deepen the organisation’s understanding of how and where the product will provide the most value. With extensive knowledge of the NHS healthcare system, Spirit Access will utilise a combination method, analysing existing data and undertaking interviews with key opinion leaders (KOL), to establish the shape of the rheumatoid arthritis patient pathway with a particular focus on the progression of the disease. The result will be a clear analysis of the current patient pathway, highlighting any areas of inefficiency.

Tony Bratt, General Manager UK, Nordic Pharma comments: “We have every confidence in the quality and value our product can provide. We knew analysing the pathway accurately would be critical so selected Spirit Access to execute an analysis of the rheumatoid arthritis pathway.

“Spirit Access stood out to us. The team has extensive experience and knowledge, which crosses over all of the stakeholders in the current healthcare system. They’ve worked in a consultative way and we’re confident that the results of the analysis will add value not only to our business but assist us in demonstrating the value we can then add to the NHS and ultimately, patients.”

David Southern, Managing Director, Spirit Access adds: “We have unparalleled experience and understanding of the NHS and with an efficient, tried and tested approach are experts in patient pathway analysis. We’re delighted to be working with Nordic Pharma to highlight any current gaps in patient care and opportunities for them to access the market, adding real value to the NHS.”



Want to find out more about our award-winning products and services?

Get in touch to see how the Spirit family of companies can help you.